NCT00307931View on ClinicalTrials.gov

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Crohn's Disease

Interventions

BIOLOGICAL

Certolizumab pegol

"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."

Trial Locations (5)

Unknown

Heraklion

Athens

Ioannina

Piraeus

Thessaloniki